2,4-Dichloropyrimidine is a versatile heterocyclic compound that finds applications in various fields, including pharmaceuticals, agrochemicals, and materials science. It is a white crystalline solid that is soluble in organic solvents. The compound is commonly synthesized through a multi-step process involving the chlorination of pyrimidine. 2,4-dichloropyrimidine serves as a key building block for the synthesis of a diverse range of biologically active compounds, such as antifungal, antibacterial, and anticancer agents. Its importance in chemical research stems from its ability to undergo various chemical reactions, including nucleophilic substitution, electrophilic aromatic substitution, and ring-opening reactions. Its versatility in chemical synthesis and its potential applications in medicinal chemistry have made it a subject of ongoing research and development.'
ID Source | ID |
---|---|
PubMed CID | 77531 |
CHEMBL ID | 3188699 |
SCHEMBL ID | 63023 |
MeSH ID | M0502390 |
Synonym |
---|
AC-2499 |
ai3-26561 |
einecs 223-508-6 |
unii-yv96122ocd |
yv96122ocd , |
nsc 37531 |
nsc 49119 |
nsc49119 |
nsc-49119 |
nsc37531 |
nsc-37531 |
pyrimidine, 2,4-dichloro- |
pyrimidine,4-dichloro- |
2,4-dichloropyrimidine , |
2,6-dichloropyrimidine |
3934-20-1 |
nsc-20212 |
nsc20212 |
inchi=1/c4h2cl2n2/c5-3-1-2-7-4(6)8-3/h1-2 |
2,4-dichloropyrimidine, 98% |
STK503789 |
nsc 20212 |
AKOS000280292 |
2,4-dichlorpyrimidin |
D2310 |
2,4-dichloro-pyrimidine |
A6589 |
tox21_202830 |
dtxcid4029149 |
NCGC00260376-01 |
cas-3934-20-1 |
dtxsid9049293 , |
2-chloropyrimidin-4-yl chloride |
BP-12063 |
FT-0601414 |
PS-5432 |
AM20100038 |
AB00576 |
CS-B0776 |
SCHEMBL63023 |
2, 4-dichloropyrimidine |
2,4-dichloropyrmidine |
2,4-dichloro-pyrmidine |
2,4 dichloro pyrimidine |
2,4 dichloropyrimidine |
2,4-di-chloropyrimidine |
2,4-dichloropyrimidin |
2,4- dichloropyrimidine |
2,4-dichloropyri-midine |
2,4-dichlorpyrimidine |
2,4 dichlorpyrimidine |
2,4dichloropyrimidine |
2.4-dichloropyrimidine |
2,4-dichloro pyrimidine |
2,4-dicloropyrimidine |
J-640154 |
W-106442 |
CHEMBL3188699 |
mfcd00006061 |
2-(2-benzothiazolylthiol)ethanol |
J-800157 |
F0001-1106 |
SY001677 |
Z99601188 |
pyrimidine,2,4-dichloro- |
BCP27299 |
pazopanib intermediates |
EN300-18947 |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 62.5359 | 3.1890 | 29.8841 | 59.4836 | AID1224846 |
GLI family zinc finger 3 | Homo sapiens (human) | Potency | 38.6292 | 0.0007 | 14.5928 | 83.7951 | AID1259369; AID1259392 |
retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 56.0224 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159553; AID1159555 |
estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 2.1999 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841 |
estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 69.5673 | 0.0002 | 29.3054 | 16,493.5996 | AID1259244 |
Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 69.5673 | 0.0015 | 57.7890 | 15,848.9004 | AID1259244 |
Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 6.9567 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 69.5673 | 0.0015 | 51.7393 | 15,848.9004 | AID1259244 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (12.50) | 29.6817 |
2010's | 5 (62.50) | 24.3611 |
2020's | 2 (25.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (36.84) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 8 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |